Form 4: Guardant Health Executive Chris Freeman Awarded Stock Options and Restricted Stock Units

Guardant Health's Chief Commercial Officer, Chris Freeman, received stock options and restricted stock units as part of his compensation package.

Summary

• Chris Freeman, Chief Commercial Officer of Guardant Health, was granted stock options and restricted stock units on November 8, 2024.
• The stock options grant consists of 45,246 shares with an exercise price of $28.61, vesting over three years.
• The restricted stock unit award is for 30,164 shares, also vesting over three years.
• Both awards have an initial vesting of 33% on October 1, 2025, with the remaining portion vesting over the subsequent two years.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which is generally positive for aligning management with shareholder interests. There are no negative aspects to the document.

Positives

• The stock option and restricted stock unit awards align the executive's interests with the company's long-term performance.
• The vesting schedule encourages long-term commitment from the executive.
• The awards are a form of compensation that does not require immediate cash outlay from the company.

Risks

• The value of the stock options and restricted stock units is dependent on the future performance of Guardant Health's stock price.
• If the stock price declines, the value of these awards will decrease.

Future Outlook

The vesting schedule of the awards indicates a long-term incentive plan for the executive.

Industry Context

Equity-based compensation is a common practice in the biotechnology and healthcare industry to attract and retain top talent.

Comparison to Industry Standards

• Stock options and restricted stock units are standard forms of executive compensation in the biotech industry, similar to companies like Exact Sciences and Illumina.
• The vesting schedule of three years with an initial cliff of 33% is also a common practice.
• The specific number of shares and exercise price would be dependent on the executive's role and the company's overall compensation strategy.

Stakeholder Impact

• Shareholders may view the awards positively as they align executive interests with company performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, restricted stock units, executive compensation, Guardant Health, Chris Freeman, vesting, equity awards